Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stryker's "mostly good" Q3 raises ortho recovery hopes

This article was originally published in Clinica

Executive Summary

Stryker’s third fiscal quarter was “mostly good,” according to Jefferies analyst Raj Denhoy, with sales growing 5% to $2.15bn, bang on analyst predictions (, 16 October 2013). The number-three orthopedic player saw “notable strength in US recon, particularly hips and extremities, and continued momentum in neurovascular, though medsurg underperformed,” wrote Mr Denhoy. Together with recent results from Biomet (, 8 October 2013) and Johnson & Johnson (, 15 October 2013), Stryker’s financials provide “more evidence of a potential uptick in US orthopedics,” he added. However, “it would be premature to declare a cyclical rebound at this point.” Stryker’s net income fell 71% to $103m, but excluding charges of $313m relating to the recalls of its Rejuvenate and ABG II modular-neck hip stems (which has cost the company $700m so far) and its Neptune waste management system, adjusted net earnings were $373m or $0.98 per share. The latter fell just short of analyst estimates of $1.00.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts